MirSNPs in Clopidogrel Metabolism Genes Predict Cardiovascular Disease Risk: A Case–Control Study And Meta-Analysis

Aim:The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods:A case–control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1rs662 with coronary artery disease. Results & conclusion:PON1rs662, PON1rs3917577, CYP3A5rs15524, COL4A1rs874204 and PTGIRrs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1rs662 on South Asian and Middle East populations.